Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 114
Summary
- Conditions
- Advanced Breast Cancer
- Breast Cancer
- Fallopian Tube Cancer
- Metastatic Breast Cancer
- Neoplasms
- Ovarian Cancer
- Peritoneal Cancer
- Stage IV Breast Cancer
- Triple -Negative Breast Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02657889
- Collaborators
- Merck Sharp & Dohme Corp.
- Investigators
- Study Director: GSK Clinical Trials GlaxoSmithKline